- Patrys (PAB) has shown its antibody can be used as a targeting agent to deliver anti-cancer drugs to tumours
- A recently completed pre-clinical study demonstrated mice treated with the company’s full-sized deoxymab antibody, PAT-DX3, showed a significantly increased survival rate compared to the control group of animals
- The company says additional studies will need to be performed to better understand the potential impacts of toxicity using this approach
- Patrys is up 4.65 per cent, trading at 4.5 cents at 1:17 pm AEDT
Patrys (PBA) has shown its antibody can be used as a targeting agent to deliver anti-cancer drugs to tumours.
A recently completed pre-clinical study demonstrated the company’s full-sized deoxymab antibody, PAT-DX3, can be used as a targeting agent for antibody drug conjugates in animal models with breast cancer.
As part of the study, Patry’s PAT-DX3-MMAE was administered to six mice per group four times throughout the duration of the study.
Patrys said the study showed this inhibition of tumour growth resulted in a significant improvement in survival in animals treated with the ADC based on Patry’s PAT-DX3 deoxymab.
After 60 days of the study, 80 per cent of the animals treated with PAT-DX3-MMAE were still alive. This was 39 days after the last treatment with PAT-DX3-MMAE was administered. By comparison, all animals in the untreated control group were euthanised due to tumour growth by the end of the study and only one animal treated in the non-specific control antibody group remained alive.
Patrys Chief Executive Officer and Managing Director, James Campbell said it was exciting to report positive data from the company’s proof-of-concept study showing that Patrys’ deoxymabs may have potential as targeting agents for ADCs.
“This preclinical study has shown that the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumours where they can inhibit tumour growth and improve survival,” Dr Campbell said.
“This exciting finding may open up new opportunities for deoxymabs as a basis for developing new therapeutic ADC products.”
The company said additional studies will need to be performed to better understand the potential impacts of on-target and off-target toxicity using this approach.
Patrys was up 4.65 per cent, trading at 4.5 cents at 1:17 pm AEDT.